
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Efficacy and safety of B/F/TAF in treatment-naïve and virologically suppressed people with HIV ≥ 50 years of age: integrated analysis from six phase 3 clinical trials - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E487118AEF552305871100278F6072.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="bmcid">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374459/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="BMC Infectious Diseases">
<meta name="citation_title" content="Efficacy and safety of B/F/TAF in treatment-naïve and virologically suppressed people with HIV ≥ 50 years of age: integrated analysis from six phase 3 clinical trials">
<meta name="citation_author" content="Cissy M Kityo">
<meta name="citation_author_institution" content="Joint Clinical Research Centre, Kampala, Uganda">
<meta name="citation_author" content="Samir K Gupta">
<meta name="citation_author_institution" content="Indiana University School of Medicine, Indianapolis, IN USA">
<meta name="citation_author" content="Princy N Kumar">
<meta name="citation_author_institution" content="Georgetown University Medical Center, Washington, DC USA">
<meta name="citation_author" content="Amy R Weinberg">
<meta name="citation_author_institution" content="Gilead Sciences, Inc, Foster City, CA USA">
<meta name="citation_author" content="Bhumi Gandhi-Patel">
<meta name="citation_author_institution" content="Gilead Sciences, Inc, Foster City, CA USA">
<meta name="citation_author" content="Hui Liu">
<meta name="citation_author_institution" content="Gilead Sciences, Inc, Foster City, CA USA">
<meta name="citation_author" content="Jason T Hindman">
<meta name="citation_author_institution" content="Gilead Sciences, Inc, Foster City, CA USA">
<meta name="citation_author" content="Jürgen K Rockstroh">
<meta name="citation_author_institution" content="University Hospital Bonn, Bonn, Germany">
<meta name="citation_publication_date" content="2025 Aug 22">
<meta name="citation_volume" content="25">
<meta name="citation_firstpage" content="1061">
<meta name="citation_doi" content="10.1186/s12879-025-11476-3">
<meta name="citation_pmid" content="40846915">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374459/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374459/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374459/pdf/12879_2025_Article_11476.pdf">
<meta name="description" content="Older adults with HIV, particularly those ≥ 50 years of age, face unique health challenges due to a higher prevalence of comorbidities and polypharmacy, which can impact medication adherence and increase the risk of adverse events. We assessed the ...">
<meta name="og:title" content="Efficacy and safety of B/F/TAF in treatment-naïve and virologically suppressed people with HIV ≥ 50 years of age: integrated analysis from six phase 3 clinical trials">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Older adults with HIV, particularly those ≥ 50 years of age, face unique health challenges due to a higher prevalence of comorbidities and polypharmacy, which can impact medication adherence and increase the risk of adverse events. We assessed the ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374459/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12374459">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s12879-025-11476-3"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/12879_2025_Article_11476.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374459%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12374459/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12374459/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374459/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-bmcid.png" alt="BMC Infectious Diseases logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to BMC Infectious Diseases" title="Link to BMC Infectious Diseases" shape="default" href="https://bmcinfectdis.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">BMC Infect Dis</button></div>. 2025 Aug 22;25:1061. doi: <a href="https://doi.org/10.1186/s12879-025-11476-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s12879-025-11476-3</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22BMC%20Infect%20Dis%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22BMC%20Infect%20Dis%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22BMC%20Infect%20Dis%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22BMC%20Infect%20Dis%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Efficacy and safety of B/F/TAF in treatment-naïve and virologically suppressed people with HIV ≥ 50 years of age: integrated analysis from six phase 3 clinical trials</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kityo%20CM%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Cissy M Kityo</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Cissy M Kityo</span></h3>
<div class="p">
<sup>1</sup>Joint Clinical Research Centre, Kampala, Uganda </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kityo%20CM%22%5BAuthor%5D" class="usa-link"><span class="name western">Cissy M Kityo</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gupta%20SK%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Samir K Gupta</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Samir K Gupta</span></h3>
<div class="p">
<sup>2</sup>Indiana University School of Medicine, Indianapolis, IN USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gupta%20SK%22%5BAuthor%5D" class="usa-link"><span class="name western">Samir K Gupta</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kumar%20PN%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Princy N Kumar</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Princy N Kumar</span></h3>
<div class="p">
<sup>3</sup>Georgetown University Medical Center, Washington, DC USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kumar%20PN%22%5BAuthor%5D" class="usa-link"><span class="name western">Princy N Kumar</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Weinberg%20AR%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Amy R Weinberg</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Amy R Weinberg</span></h3>
<div class="p">
<sup>4</sup>Gilead Sciences, Inc, Foster City, CA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Weinberg%20AR%22%5BAuthor%5D" class="usa-link"><span class="name western">Amy R Weinberg</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gandhi-Patel%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Bhumi Gandhi-Patel</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Bhumi Gandhi-Patel</span></h3>
<div class="p">
<sup>4</sup>Gilead Sciences, Inc, Foster City, CA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gandhi-Patel%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Bhumi Gandhi-Patel</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Hui Liu</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Hui Liu</span></h3>
<div class="p">
<sup>4</sup>Gilead Sciences, Inc, Foster City, CA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hui Liu</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hindman%20JT%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Jason T Hindman</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Jason T Hindman</span></h3>
<div class="p">
<sup>4</sup>Gilead Sciences, Inc, Foster City, CA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hindman%20JT%22%5BAuthor%5D" class="usa-link"><span class="name western">Jason T Hindman</span></a>
</div>
</div>
<sup>4,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rockstroh%20JK%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Jürgen K Rockstroh</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Jürgen K Rockstroh</span></h3>
<div class="p">
<sup>5</sup>University Hospital Bonn, Bonn, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rockstroh%20JK%22%5BAuthor%5D" class="usa-link"><span class="name western">Jürgen K Rockstroh</span></a>
</div>
</div>
<sup>5</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Joint Clinical Research Centre, Kampala, Uganda </div>
<div id="Aff2">
<sup>2</sup>Indiana University School of Medicine, Indianapolis, IN USA </div>
<div id="Aff3">
<sup>3</sup>Georgetown University Medical Center, Washington, DC USA </div>
<div id="Aff4">
<sup>4</sup>Gilead Sciences, Inc, Foster City, CA USA </div>
<div id="Aff5">
<sup>5</sup>University Hospital Bonn, Bonn, Germany </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Mar 4; Accepted 2025 Jul 31; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12374459  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40846915/" class="usa-link">40846915</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Introduction</h3>
<p id="Par1">Older adults with HIV, particularly those ≥ 50 years of age, face unique health challenges due to a higher prevalence of comorbidities and polypharmacy, which can impact medication adherence and increase the risk of adverse events. We assessed the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV (PWH) ≥ 50 years of age across treatment-naïve and virologically suppressed cohorts over a long-term follow-up.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">This post hoc analysis included participants ≥ 50 and &lt; 50 years of age from six phase 3 trials of B/F/TAF, comprising 2 treatment-naïve studies and 4 virologically suppressed studies. Outcomes were assessed through Week 240 for the treatment-naïve cohort and Week 48 for the virologically suppressed cohort. Key measures included virologic outcomes (HIV-1 RNA &lt; 50 or ≥ 50 copies/mL), CD4 T-cell changes, adherence, metabolic and renal parameters, treatment-emergent adverse events, and treatment-emergent diabetes and hypertension.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">The treatment-naïve cohort included 96 participants ≥ 50 years of age and 538 participants &lt; 50 years of age, while the virologically suppressed cohort included 450 participants ≥ 50 years of age and 640 participants &lt; 50 years of age. By Week 240, virologic suppression was achieved in 98.5% of treatment-naïve participants ≥ 50 years of age and in 98.6% of those &lt; 50 years of age, as determined using missing = excluded analysis. By Week 48, virologic failure was 0.9% versus 1.4% in participants ≥ 50 years of age versus &lt; 50 years of age, respectively, and virologic suppression was maintained in 93.6% of virologically suppressed participants in both the ≥ 50 and &lt; 50 years of age groups, as assessed using the US Food and Drug Administration snapshot algorithm. Across age groups, the treatment-naïve and virologically suppressed cohorts demonstrated comparable outcomes beyond viral load through Weeks 240 and 48, respectively, including CD4 T-cell changes, adherence rates of ≥ 95%, body weight, lipid profiles, renal function, bone health, treatment-emergent adverse events, and the incidence of treatment-emergent diabetes and hypertension.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusions</h3>
<p id="Par4">These results highlight the durability, long-term efficacy, safety, and overall benefits of B/F/TAF in PWH ≥ 50 years of age.</p></section><section id="sec5"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1186/s12879-025-11476-3.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> HIV, Older adults, B/F/TAF, Antiretroviral therapy, Comorbidities</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par25">Antiretroviral therapy (ART) has greatly improved the life expectancy of people with HIV; PWH), changing the demographic characteristics of the epidemic [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>, <a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>]. Presently, an estimated 24% of the global HIV-positive population is ≥ 50 years of age [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. As the global population of PWH ≥ 50 years of age continues to increase, so does the need for ART regimens that address the unique health challenges of this aging cohort [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>–<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>]. Older PWH frequently experience higher rates of age-related comorbidities, such as cardiovascular disease, diabetes, and hypertension, which is often exacerbated by long-term ART exposure; these comorbidities, combined with prolonged ART use, increase the risk of adverse drug events and present specific challenges in managing bone health, renal function, metabolic parameters, cardiovascular health, and other conditions [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>–<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>].</p>
<p id="Par26">Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet regimen that has shown efficacy and safety in treatment-naïve participants and those who are virologically suppressed [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>–<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. Its formulation, which includes tenofovir alafenamide (TAF), offers improved renal and bone safety profiles compared with tenofovir disoproxil fumarate (TDF)–based treatments, which is particularly relevant for aging adults with comorbidities [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>–<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. However, data on the long-term use of B/F/TAF in older adults remain limited, especially regarding its efficacy and safety in managing the complex health profiles of PWH ≥ 50 years of age.</p>
<p id="Par27">To address this gap, our study pools data from six phase 3 clinical trials to evaluate the long-term efficacy and safety of B/F/TAF in participants ≥ 50 years of age, encompassing both treatment-naïve and virologically suppressed populations. By focusing on this demographic, our study aims to inform best practices for managing HIV in aging populations and to reduce disparities in health outcomes for older PWH.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Overall study design and participants (supplemental fig. 1)</h3>
<p id="Par28">This post hoc analysis utilized data from 2 cohorts across six phase 3 clinical trials to evaluate the long-term efficacy and safety of B/F/TAF in PWH ≥ 50 years of age. The study included participants who were both treatment-naïve and virologically suppressed. For the treatment-naïve cohort, participants were drawn from B/F/TAF group (randomized to B/F/TAF) of Studies 1489 (ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT02607930" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02607930</a>; Clinical trial number: not applicable) and 1490 (<a href="https://clinicaltrials.gov/ct2/show/NCT02607956" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02607956</a>). In these trials, eligible participants had plasma HIV-1 RNA levels ≥ 500 copies/mL at screening and were ART-naïve. Study 1489 excluded individuals with chronic hepatitis B virus (HBV) infection or HLA-B*5701 positivity and required an estimated glomerular filtration rate (eGFR) ≥ 50 mL/min, while Study 1490 allowed participants with chronic HBV or hepatitis or C virus infection and required an eGFR ≥ 30 mL/min. The methods for both studies have been previously published [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>, <a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>].</p>
<p id="Par29">For the virologically suppressed cohort, participants were selected from the B/F/TAF group (randomized to B/F/TAF) of Studies 1844 (<a href="https://clinicaltrials.gov/ct2/show/NCT02603120" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02603120</a>), 1878 (<a href="https://clinicaltrials.gov/ct2/show/NCT02603107" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02603107</a>), 1961 (<a href="https://clinicaltrials.gov/ct2/show/NCT02652624" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02652624</a>), and 4030 (<a href="https://clinicaltrials.gov/ct2/show/NCT03110380" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03110380</a>). Specifically, Study 1844 did not require stable suppression (&lt; 50 copies/mL) for ≥ 6 months before switching; whereas, Study 4030 included participants with documented suppression of HIV-1 RNA &lt; 50 copies/mL for a minimum period of ≥ 3 or ≥ 6 months depending on the preceding treatment regimen (dolutegravir + emtricitabine/TAF or dolutegravir + emtricitabine/TDF) and the assay sensitivity (with a threshold of ≥ 50 copies/mL, as applicable). Throughout the studies, virologically suppressed participants were required to maintain viral suppression and were excluded if they modified lipid-lowering medications or other ART regimens that could influence study outcomes.</p>
<p id="Par30">All the studies were conducted in accordance with the Declaration of Helsinki and approved by the US Food and Drug Administration (FDA). Institutional review boards at each site granted ethical approval, and all participants provided written informed consent.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Study outcomes and assessments</h3>
<p id="Par31">This analysis reports efficacy and safety outcomes among participants ≥ 50 years of age in 2 cohorts across 6 studies that assessed B/F/TAF treatment. The treatment-naïve cohort included participants who were randomized to B/F/TAF and received B/F/TAF up to Week 240 (end of study). For the virologically suppressed cohort, the studies included participants who were randomized to B/F/TAF and who received B/F/TAF up to the Week 48 analysis data cutoff of the randomized phase.</p>
<p id="Par32">In all 6 studies, plasma HIV-1 RNA levels were measured using the Roche TaqMan™ 2.0 assay (Roche Diagnostics, Rotkreuz, Switzerland), and CD4 T-cell counts were assessed at baseline (Day 1) followed by Weeks 4, 8, and 12, and subsequently every 12 weeks throughout the randomized phase. Additionally, lipid profiles (total cholesterol [TC], high-density lipoprotein [HDL] cholesterol, direct low-density lipoprotein [LDL] cholesterol, and triglycerides) were measured after an 8-hour fast at baseline, and assessments were conducted at Weeks 12, 24, 48, 72, 96, 120, and 144 for the treatment-naïve cohort, with continued assessments every 12 weeks. For the virologically suppressed cohort, assessments were conducted at Weeks 12, 24, and 48.</p>
<p id="Par33">The efficacy outcomes included the proportion of participants with plasma HIV-1 RNA &lt; 50 copies/mL at Week 240 for the treatment-naïve cohort, which was analyzed using missing = excluded (M = E) and missing = failure (M = F) methods (with imputation of missing data as exclusion and failure, respectively), and the proportion of participants with plasma HIV-1 RNA &lt; 50 or ≥ 50 copies/mL at Week 48 for the virologically suppressed cohort, which was analyzed primarily using the FDA snapshot method (with the proportion of participants with plasma HIV-1 RNA &lt; 50 copies/mL at Week 48 by M = E and M = F methods as other efficacy outcomes). Change in CD4 T-cell count from baseline to Week 240 (for the treatment-naïve cohort) and to Week 48 (for the virologically suppressed cohort) was also another efficacy outcome.</p>
<p id="Par34">Other outcomes focused on safety, examining changes in renal function (eGFR) and bone mineral density (BMD) as indicators of long-term treatment impact. BMD was measured using dual x-ray absorptiometry scans, which were available at Week 240 for the treatment-naïve cohort in Study 1489 and at Week 48 for the virologically suppressed cohorts. Metabolic parameters, including changes in body weight and fasting lipid levels, were assessed to identify any treatment-emergent metabolic effects. Treatment-emergent adverse events (TEAEs) and new-onset diabetes mellitus, hypertension, and any treatment-emergent viral resistance were monitored. Adherence to the B/F/TAF regimen was assessed through pill counts, with adherence rates ≥ 95% classified as high and &lt; 85% classified as low.</p>
<p id="Par35">The analysis also accounted for metabolic comorbidities and renal outcomes, which were reported using standardized <em>Medical Dictionary for Regulatory Activities</em> query (SMQ; version 24.0 for the treatment-naïve cohort and version 26.1 for the virologically suppressed cohort) search lists through Week 240 for the treatment-naïve cohort or through Week 48 for the virologically suppressed cohort. New diagnoses of diabetes mellitus and hypertension were identified via the hyperglycemia/new-onset diabetes mellitus SMQ (narrow scope) and hypertension SMQ, respectively. Participants with a history of diabetes or hypertension at baseline were excluded from the respective treatment-emergent diabetes or hypertension assessments.</p></section><section id="Sec5"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par36">Baseline demographic and clinical characteristics were summarized using descriptive statistics, including means and standard deviations (SDs) for continuous variables and proportions for categorical variables. The proportion of participants with plasma HIV-1 RNA &lt; 50 copies/mL at Week 240 for the treatment-naïve cohort using M = E and M = F methods was summarized. The difference in the percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 240 between age groups and its 95% confidence interval (CI) were calculated based on Mantel-Haenszel proportions and adjusted by baseline HIV-1 RNA stratum (≤ 100000 vs. &gt; 100000 copies/mL) and region stratum (US vs. Ex-US). The difference in the percentage of participants with HIV-1 RNA ≥ 50 or &lt; 50 copies/mL at Week 48 by snapshot algorithm between age groups and its 95% CI was calculated using an unconditional exact method with 2 inverted 1-sided tests. <em>P</em> values for comparing the 2 age groups were derived from the Fisher exact test. In general, no adjustment for multiplicity was made for outcomes evaluated in this post hoc analysis. Nominal <em>P</em> values (<em>P</em> values without multiplicity adjustment) were provided.</p>
<p id="Par37">Change in CD4 T-cell count from baseline to Week 240 for the treatment-naïve cohort and to Week 48 for the virologically suppressed cohort was compared between age groups using an analysis of variance model, with age group as a fixed effect. Between treatment groups, the difference in adherence categories (≥ 95%, ≥ 85 to &lt; 95%, and &lt; 85%) was compared using the Cochran-Mantel-Haenszel statistics test.</p>
<p id="Par38">TEAEs, fasting lipids, weight changes, and metabolic outcomes, including treatment-emergent diabetes mellitus and hypertension, were analyzed descriptively. In addition, for continuous metabolic and renal outcomes, such as fasting lipids (TC, LDL, HDL, triglycerides, and TC ratio) and weight changes from baseline, the 2-sided Wilcoxon rank sum test was used for age group comparison of continuous variables. Fisher’s exact test was applied for age group comparison of categorical outcomes, including treatment-emergent diabetes mellitus and hypertension. Safety data were summarized, covering all data from the first dose of study drug to the data cutoff date or up to 30 days after treatment discontinuation, if applicable. All statistical analysis were conducted using SAS software (version 9.4).</p></section></section><section id="Sec6"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec7"><h3 class="pmc_sec_title">Participant demographic and baseline characteristics</h3>
<p id="Par39">In this pooled analysis of 2 cohorts from 6 studies that assessed B/F/TAF in participants ≥ 50 years of age (compared with participants &lt; 50 years of age), baseline characteristics were evaluated across both treatment-naïve and virologically suppressed cohorts (Table <a href="#Tab1" class="usa-link">1</a>).</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Demographics and characteristics</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="2" rowspan="1"></th>
<th align="left" colspan="2" rowspan="1">Treatment-naïve cohort</th>
<th align="left" colspan="2" rowspan="1">Virologically suppressed cohort</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="3" colspan="2">Median (Q1, Q3) age, years</td>
<td align="left" colspan="1" rowspan="1">≥50 years</td>
<td align="left" colspan="1" rowspan="1">&lt;50 years</td>
<td align="left" colspan="1" rowspan="1">≥50 years</td>
<td align="left" colspan="1" rowspan="1">&lt;50 years</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<em>n</em> = 96</td>
<td align="left" colspan="1" rowspan="1">
<em>n</em> = 538</td>
<td align="left" colspan="1" rowspan="1">
<em>n</em> = 450</td>
<td align="left" colspan="1" rowspan="1">
<em>n</em> = 640</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">55 (52, 60)</td>
<td align="left" colspan="1" rowspan="1">30 (25, 37)</td>
<td align="left" colspan="1" rowspan="1">56 (52,60)</td>
<td align="left" colspan="1" rowspan="1">39 (33,45)</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">Male sex at birth, n (%)</td>
<td align="left" colspan="1" rowspan="1">81 (84.4)</td>
<td align="left" colspan="1" rowspan="1">484 (90.0)</td>
<td align="left" colspan="1" rowspan="1">342 (76.0)</td>
<td align="left" colspan="1" rowspan="1">393 (61.4)</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Region, n (%)</td>
<td align="left" colspan="1" rowspan="1">US</td>
<td align="left" colspan="1" rowspan="1">56 (58.3)</td>
<td align="left" colspan="1" rowspan="1">365 (67.8)</td>
<td align="left" colspan="1" rowspan="1">327 (72.7)</td>
<td align="left" colspan="1" rowspan="1">294 (45.9)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ex-US</td>
<td align="left" colspan="1" rowspan="1">40 (41.7)</td>
<td align="left" colspan="1" rowspan="1">173 (32.2)</td>
<td align="left" colspan="1" rowspan="1">123 (27.3)</td>
<td align="left" colspan="1" rowspan="1">346 (54.1)</td>
</tr>
<tr>
<td align="left" rowspan="3" colspan="1">Race, n (%)</td>
<td align="left" colspan="1" rowspan="1">White</td>
<td align="left" colspan="1" rowspan="1">59 (61.5)</td>
<td align="left" colspan="1" rowspan="1">304 (56.5)</td>
<td align="left" colspan="1" rowspan="1">291 (64.7)</td>
<td align="left" colspan="1" rowspan="1">369 (57.7)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Black</td>
<td align="left" colspan="1" rowspan="1">30 (31.3)</td>
<td align="left" colspan="1" rowspan="1">181 (33.7)</td>
<td align="left" colspan="1" rowspan="1">131 (29.1)</td>
<td align="left" colspan="1" rowspan="1">166 (25.9)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Other<sup>a</sup>
</td>
<td align="left" colspan="1" rowspan="1">4 (4.2)<sup>b</sup>
</td>
<td align="left" colspan="1" rowspan="1">36 (6.7)<sup>b</sup>
</td>
<td align="left" colspan="1" rowspan="1">17 (3.8)<sup>b</sup>
</td>
<td align="left" colspan="1" rowspan="1">38 (5.9)<sup>b</sup>
</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">Hispanic or Latino ethnicity, n (%)</td>
<td align="left" colspan="1" rowspan="1">11 (11.5)</td>
<td align="left" colspan="1" rowspan="1">144 (26.9)<sup>c</sup>
</td>
<td align="left" colspan="1" rowspan="1">72 (16.0)<sup>c</sup>
</td>
<td align="left" colspan="1" rowspan="1">131 (20.5)<sup>d</sup>
</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">HIV-1 RNA log<sub>10</sub> c/mL (Q1, Q3)</td>
<td align="left" colspan="1" rowspan="1">4.5 (4.0, 4.9)</td>
<td align="left" colspan="1" rowspan="1">4.4 (4.0, 4.9)</td>
<td align="left" colspan="1" rowspan="1">N/A</td>
<td align="left" colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">HIV-1 RNA &lt; 50 c/mL, n (%)</td>
<td align="left" colspan="1" rowspan="1">N/A</td>
<td align="left" colspan="1" rowspan="1">N/A</td>
<td align="left" colspan="1" rowspan="1">441 (98.0)</td>
<td align="left" colspan="1" rowspan="1">632 (98.8)</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">HIV-1 RNA &gt; 100,000 c/mL, n (%)</td>
<td align="left" colspan="1" rowspan="1">23 (24.0)</td>
<td align="left" colspan="1" rowspan="1">96 (17.8)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">CD4 T-cell count, cells/µL, median (IQR)</td>
<td align="left" colspan="1" rowspan="1">436 (235–601)</td>
<td align="left" colspan="1" rowspan="1">442 (299–590)</td>
<td align="left" colspan="1" rowspan="1">640 (486–852)</td>
<td align="left" colspan="1" rowspan="1">691 (523–887)</td>
</tr>
<tr>
<td align="left" rowspan="3" colspan="1">Medical history, n (%)</td>
<td align="left" colspan="1" rowspan="1">Cardiovascular disease</td>
<td align="left" colspan="1" rowspan="1">6 (6.3)</td>
<td align="left" colspan="1" rowspan="1">8 (1.5)</td>
<td align="left" colspan="1" rowspan="1">50 (11.1)</td>
<td align="left" colspan="1" rowspan="1">15 (2.3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Diabetes mellitus</td>
<td align="left" colspan="1" rowspan="1">16 (16.7)</td>
<td align="left" colspan="1" rowspan="1">22 (4.1)</td>
<td align="left" colspan="1" rowspan="1">76 (16.9)</td>
<td align="left" colspan="1" rowspan="1">38 (5.9)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hyperlipidemia</td>
<td align="left" colspan="1" rowspan="1">39 (40.6)</td>
<td align="left" colspan="1" rowspan="1">48 (8.9)</td>
<td align="left" colspan="1" rowspan="1">220 (48.9)</td>
<td align="left" colspan="1" rowspan="1">121 (18.9)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Hypertension</td>
<td align="left" colspan="1" rowspan="1">46 (47.9)</td>
<td align="left" colspan="1" rowspan="1">52 (9.7)</td>
<td align="left" colspan="1" rowspan="1">182 (40.4)</td>
<td align="left" colspan="1" rowspan="1">111 (17.3)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p23">
<p><em>c</em> copies, <em>HIV-1</em> Human immunodeficiency virus–1, <em>IQR</em> Interquartile range, <em>N/A</em> Not applicable</p>
<p><sup>a</sup>Includes American Indian or Alaska Native, Asian, Native Hawaiian or Pacific Islander, and other</p>
<p><sup>b</sup>Race data were not available for 1 participant</p>
<p><sup>c</sup>Ethnicity data were not available for 1 participant</p>
<p><sup>d</sup>Ethnicity data were not available for 2 participants</p>
</div></div></section><p id="Par41">Among treatment-naïve participants, the median age was 55 years (quartile [Q]1, Q3: 52, 60) for those ≥ 50 years of age (<em>n</em> = 96) and 30 years (Q1, Q3: 25, 37) for those &lt; 50 years of age (<em>n</em> = 538). This cohort included 5 participants ≥ 65 years of age, 91 participants 50 to &lt; 65 years of age, and 538 participants &lt; 50 years of age, for a total of 634 participants in the B/F/TAF analysis set. The majority of participants were male at birth, with 84.4% in the ≥ 50 years of age group and 90.0% in the &lt; 50 years of age. Regionally, 58.3% of participants ≥ 50 years of age and 67.8% of those &lt; 50 years of age were from the United States, with the remainder from other countries. Racially, 61.5% of participants ≥ 50 years of age and 56.5% of those &lt; 50 years of age identified as White, while 31.3% and 33.7%, respectively, identified as Black. Hispanic or Latino ethnicity was reported by 11.5% of participants ≥ 50 years of age and 26.9% of those &lt; 50 years of age. Median baseline HIV-1 RNA level was 4.48 log<sub>10</sub> copies/mL (Q1, Q3: 4.00, 4.93) for participants ≥ 50 years of age and 4.41 log<sub>10</sub> copies/mL (Q1, Q3: 4.00, 4.86) for those &lt; 50 years of age. CD4 T-cell counts were similar, with a median of 436 cells/µL (Q1, Q3: 235, 601) in the ≥ 50 years of age group and 442 cells/µL (Q1, Q3: 299, 590) in the &lt; 50 years of age group. Among participants ≥ 50 years of age, 16.7% had diabetes, 6.3% had cardiovascular disease, 40.6% had hyperlipidemia, and 47.9% had hypertension. Among participants &lt; 50 years of age, 4.1% had diabetes, 1.5% had cardiovascular disease, 8.9% had hyperlipidemia, and 9.7% had hypertension (Table <a href="#Tab1" class="usa-link">1</a>).</p>
<p id="Par42">For the virologically suppressed cohort, the median age was 56 years (Q1, Q3: 52, 60) for participants ≥ 50 years of age (<em>n</em> = 450) and 39 years (Q1, Q3: 33, 45) for those &lt; 50 years of age (<em>n</em> = 640). This cohort included 54 participants ≥ 65 years of age, 396 participants 50 to &lt; 65 years of age, and 640 participants &lt; 50 years of age, for a total of 1090 in the B/F/TAF safety analysis set. Most participants were male at birth, with 76.0% in the ≥ 50 years of age group and 61.4% in the &lt; 50 years of age group. In terms of region, 72.7% of those ≥ 50 years of age and 45.9% of those &lt; 50 years of age were from the United States. Among those ≥ 50 years of age, 64.7% of participants identified as White, 29.1% identified as Black, and 16.0% reported Hispanic or Latino ethnicity. In the &lt; 50 years of age group, 57.7% of participants identified as White, 25.9% identified as Black, and 20.5% reported Hispanic or Latino ethnicity. Baseline virologic suppression was high, with 98.0% (441/450) of those ≥ 50 years of age and 98.8% (632/640) of those &lt; 50 years of age having HIV-1 RNA &lt; 50 copies/mL. Median CD4 T-cell counts were 640 cells/µL (Q1, Q3: 486, 852) for participants ≥ 50 years of age and 691 cells/µL (Q1, Q3: 523, 887) for those &lt; 50 years of age. Medical history showed a notable prevalence of comorbidities among those ≥ 50 years of age: 11.1% of participants had cardiovascular disease, 16.9% had diabetes, 48.9% had hyperlipidemia, and 40.4% had hypertension. Among those &lt; 50 years of age, 2.3% of participants had cardiovascular disease, 5.9% had diabetes, 18.9% had hyperlipidemia, and 17.3% had hypertension (Table <a href="#Tab1" class="usa-link">1</a>).</p></section><section id="Sec8"><h3 class="pmc_sec_title">Virologic Outcomes</h3>
<p id="Par43">In the treatment-naïve cohort, virologic suppression (HIV-1 RNA &lt; 50 copies/mL) at Week 240 was achieved by 98.5% of participants (67/68) ≥ 50 years of age (95% CI: 92.1%−100.0%) and by 98.6% of participants (359/364) &lt; 50 years of age (95% CI: 96.8%−99.6%), as determined by the M = E analysis (<em>P</em> = 0.9139; Fig. <a href="#Fig1" class="usa-link">1</a>A). In the M = F analysis, virologic suppression at Week 240 was maintained by 69.8% of participants (67/96) ≥ 50 years of age (95% CI: 59.6%−78.7%) and by 66.7% of participants (359/538) &lt; 50 years of age (95% CI: 62.6%−70.7%), with no significant differences observed between the 2 age groups (<em>P</em> = 0.50).</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374459_12879_2025_11476_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6ac/12374459/1ef296f75551/12879_2025_11476_Fig1_HTML.jpg" loading="lazy" id="d33e800" height="659" width="669" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Virologic outcomes (M = E) in the treatment-naïve (<strong>A</strong>) and virologically suppressed (<strong>B</strong>) cohorts. B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; c, copies; HIV-1, human immunodeficiency virus–1; M = E, missing = excluded. Results are shown using the M=E approach unless otherwise indicated. <strong>A</strong> Treatment-naïve cohort: the rate of virologic suppression (HIV-1 RNA&lt;50 c/mL) with B/F/TAF was similar at Week 240 between age groups (M = E). <strong>B</strong> Virologically suppressed cohort: the rate of virologic failure (HIV-1 RNA ≥50 c/mL) was low and virologic suppression (HIV-1 RNA &lt;50 c/mL) was high with B/F/TAF at Week 48 in both age groups (FDA Snapshot)</p></figcaption></figure><p id="Par45">At Week 48 in the virologically suppressed cohort, virologic suppression (HIV-1 RNA &lt; 50 copies/mL), as assessed by the FDA snapshot method, was achieved by 93.6% of participants, with 93.6% of participants (421/450; 95% CI: 90.9%−95.6%) ≥ 50 years of age and 93.6% of participants (599/640; 95% CI: 91.4%−95.4%) &lt; 50 years of age achieving suppression; there were no statistically significant differences between the 2 groups (<em>P</em> = 1.00; Fig. <a href="#Fig1" class="usa-link">1</a>B). The proportion of participants with HIV-1 RNA ≥ 50 copies/mL was 0.9% (4/450; 95% CI: 0.2%−2.3%) for participants ≥ 50 years of age and 1.4% (9/640; 95% CI: 0.6%−2.7%) for those &lt; 50 years of age, with no statistically significant differences between the 2 groups (<em>P</em> = 0.58; Fig. <a href="#Fig1" class="usa-link">1</a>B). At Week 48, virologic suppression (HIV-1 RNA &lt; 50 copies/mL) was achieved by 99.3% of participants (426/429; 95% CI: 98.0%−99.9%) ≥ 50 years of age and 98.7% of participants (602/610; 95% CI: 97.4%−99.4%) &lt; 50 years of age in the M = E analysis. The difference between the 2 age groups was not statistically significant (<em>P</em> = 0.54). At Week 48, virologic suppression (HIV-1 RNA &lt; 50 copies/mL) was achieved by 94.7% of participants (426/450; 95% CI: 92.2%−96.6%) ≥ 50 years of age and 94.1% of participants (602/640; 95% CI: 91.9%−95.8%) &lt; 50 years of age in the M = F analysis. The difference between the 2 age groups was not statistically significant (<em>P</em> = 0.69). No treatment-emergent resistance to B/F/TAF was observed in either age group through Week 240 in the treatment-naïve cohort or through Week 48 in the virologically suppressed cohort.</p></section><section id="Sec9"><h3 class="pmc_sec_title">CD4 T-cell counts </h3>
<p id="Par46">At Week 240 in the treatment-naïve cohort, CD4 T-cell counts continued to increase from baseline in both age groups (mean [SD] change from baseline: +291 [221.3] for participants ≥ 50 years of age and + 347 [238.2] for those &lt; 50 years of age; least squares mean difference [LSMD]: − 58 [range: − 120, 4]; <em>P</em> = 0.07). At Week 48 in the virologically suppressed cohort, CD4 T-cell count also increased from baseline among participants ≥ 50 years of age and those &lt; 50 years of age (mean [SD] change from baseline: +18 [162.5] and + 4 [174.9] cells/µL, respectively; LSMD: 15 [range: − 7, 36]; <em>P</em> = 0.18), indicating no statistically significant difference between age groups.</p></section><section id="Sec10"><h3 class="pmc_sec_title">Adherence</h3>
<p id="Par47">Adherence to B/F/TAF through Week 240 for the treatment-naïve cohort and through Week 48 for the virologically suppressed cohort is shown in Table <a href="#Tab2" class="usa-link">2</a>. In the treatment-naïve cohort, the median adherence rate was high in both age groups, with participants ≥ 50 years of age showing a median (Q1, Q3) adherence of 98.2% (96.7, 99.4) and those &lt; 50 years of age at 97.0% (93.2, 98.9). A greater proportion of participants ≥ 50 years of age achieved an adherence rate of ≥ 95% compared with those &lt; 50 years of age (82.8% vs. 66.3%, respectively; <em>P</em> = 0.002; Table <a href="#Tab2" class="usa-link">2</a>). In the virologically suppressed cohort, the median adherence rate was also high for both age groups at Week 48, with a median (Q1, Q3) adherence of 98.8% (96.8, 99.7) for participants ≥ 50 years of age and 98.8% (96.8, 99.7) for those &lt; 50 years of age. The proportion of participants with adherence rates of ≥ 95%, ≥ 85 to &lt; 95%, and &lt; 85% was similar between age groups, indicating consistent adherence across age categories in the virologically suppressed cohort (Table <a href="#Tab2" class="usa-link">2</a>).</p>
<section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Adherence</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="3" colspan="1"></th>
<th align="left" colspan="2" rowspan="1">Treatment-naïve cohort</th>
<th align="left" colspan="2" rowspan="1">Virologically suppressed cohort</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">≥ 50 years of age</th>
<th align="left" colspan="1" rowspan="1">&lt; 50 years of age</th>
<th align="left" colspan="1" rowspan="1">≥ 50 years of age</th>
<th align="left" colspan="1" rowspan="1">&lt; 50 years of age</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">
<em>n</em> = 96</th>
<th align="left" colspan="1" rowspan="1">
<em>n</em> = 538</th>
<th align="left" colspan="1" rowspan="1">
<em>n</em> = 450</th>
<th align="left" colspan="1" rowspan="1">
<em>n</em> = 640</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Participants who returned ≥ 1 bottle, n (%)</td>
<td align="left" colspan="1" rowspan="1">93 (96.9)</td>
<td align="left" colspan="1" rowspan="1">531 (98.7)</td>
<td align="left" colspan="1" rowspan="1">448 (99.6)</td>
<td align="left" colspan="1" rowspan="1">639 (99.8)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Median</p>
<p>(Q1, Q3) adherence, %</p>
</td>
<td align="left" colspan="1" rowspan="1">98.2 (96.7, 99.4)</td>
<td align="left" colspan="1" rowspan="1">97.0 (93.2, 98.9)</td>
<td align="left" colspan="1" rowspan="1">98.8 (96.8, 99.7)</td>
<td align="left" colspan="1" rowspan="1">98.8 (96.8, 99.7)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">&lt; 85%, n (%)</td>
<td align="left" colspan="1" rowspan="1">5 (5.4)</td>
<td align="left" colspan="1" rowspan="1">39 (7.3)</td>
<td align="left" colspan="1" rowspan="1">11 (2.5)</td>
<td align="left" colspan="1" rowspan="1">15 (2.3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">≥ 85% to &lt; 95%, n (%)</td>
<td align="left" colspan="1" rowspan="1">11 (11.8)</td>
<td align="left" colspan="1" rowspan="1">140 (26.4)</td>
<td align="left" colspan="1" rowspan="1">62 (13.8)</td>
<td align="left" colspan="1" rowspan="1">79 (12.4)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">≥ 95%, n (%)</td>
<td align="left" colspan="1" rowspan="1">77 (82.8)</td>
<td align="left" colspan="1" rowspan="1">352 (66.3)</td>
<td align="left" colspan="1" rowspan="1">375 (83.7)</td>
<td align="left" colspan="1" rowspan="1">545 (85.3)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p40">
<p>Adherence was calculated based on pill count for the study drug (B/F/TAF). Denominator for the percentage of drug adherence was the number of participants who returned ≥ 1 bottle and had calculable drug adherence. For the treatment-naïve cohort, adherence was measured through Week 240 (end of study). For the virologically suppressed cohort, adherence was measured through Week 48</p>
<p><em>B/F/TAF</em> Bictegravir/emtricitabine/tenofovir alafenamide, <em>Q</em> Quartile</p>
</div></div></section></section><section id="Sec11"><h3 class="pmc_sec_title">Outcomes in body weight, lipid profile, renal function, and bone health</h3>
<p id="Par49">Change from baseline in body weight through Week 240 is shown for participants ≥ 50 and &lt; 50 years of age in the treatment-naïve cohort and through Week 48 for the virologically suppressed cohort. In the treatment-naïve cohort, there were no significant overall differences in weight change at Week 240 between participants ≥ 50 years of age and those &lt; 50 years of age. The median (Q1, Q3) weight gain was 4.8 kg (0.7, 10.2) for participants ≥ 50 years of age and 6.4 kg (2.4, 12.0) for those &lt; 50 years of age. At Week 48 in the virologically suppressed cohort, change in body weight was minimal, with a median (Q1, Q3) weight gain of 1.5 kg (–0.8, 3.8) for participants ≥ 50 years of age and 1.8 kg (–0.4, 4.0) for those &lt; 50 years of age. No significant difference in weight change was observed between age groups in either cohort (Table <a href="#Tab3" class="usa-link">3</a> and Supplement Table <a href="#Tab1" class="usa-link">1</a>).</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Bone, renal, and metabolic outcomes</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="2" colspan="2"></th>
<th align="left" colspan="5" rowspan="1">Treatment-naïve cohort</th>
<th align="left" colspan="6" rowspan="1">Virologically suppressed cohort</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">≥ 50 years of age</th>
<th align="left" colspan="1" rowspan="1">N</th>
<th align="left" colspan="1" rowspan="1">&lt; 50 years of age</th>
<th align="left" colspan="1" rowspan="1">N</th>
<th align="left" colspan="1" rowspan="1">
<em>P</em> value</th>
<th align="left" colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">≥ 50 years of age</th>
<th align="left" colspan="1" rowspan="1">N</th>
<th align="left" colspan="1" rowspan="1">&lt; 50 years of age</th>
<th align="left" colspan="1" rowspan="1">N</th>
<th align="left" colspan="1" rowspan="1">
<em>P</em> value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="2" colspan="1">
<p>Median body weight, kg</p>
<p>(Q1, Q3)</p>
</td>
<td align="left" colspan="1" rowspan="1">Baseline</td>
<td align="left" colspan="1" rowspan="1">79.3 (70.7, 89.9)</td>
<td align="left" colspan="1" rowspan="1">96</td>
<td align="left" colspan="1" rowspan="1">75.9 (67.3, 87.1)</td>
<td align="left" colspan="1" rowspan="1">538</td>
<td align="left" colspan="1" rowspan="1">0.0285</td>
<td align="left" colspan="1" rowspan="1">Baseline</td>
<td align="left" colspan="1" rowspan="1">81.1 (71.9, 92.5)</td>
<td align="left" colspan="1" rowspan="1">450</td>
<td align="left" colspan="1" rowspan="1">76.0 (66.0, 87.1)</td>
<td align="left" colspan="1" rowspan="1">640</td>
<td align="left" colspan="1" rowspan="1">&lt; 0.0001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Change at Week 240</td>
<td align="left" colspan="1" rowspan="1">4.8 (0.7, 10.2)</td>
<td align="left" colspan="1" rowspan="1">68</td>
<td align="left" colspan="1" rowspan="1">6.4 (2.4, 12.0)</td>
<td align="left" colspan="1" rowspan="1">363</td>
<td align="left" colspan="1" rowspan="1">0.087</td>
<td align="left" colspan="1" rowspan="1">Change at Week 48</td>
<td align="left" colspan="1" rowspan="1">1.5 (–0.8, 3.8)</td>
<td align="left" colspan="1" rowspan="1">429</td>
<td align="left" colspan="1" rowspan="1">1.8 (–0.4, 4.0)</td>
<td align="left" colspan="1" rowspan="1">609</td>
<td align="left" colspan="1" rowspan="1">0.2857</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">
<p>Median TC: HDL ratio</p>
<p>(Q1, Q3)<sup>a</sup></p>
</td>
<td align="left" colspan="1" rowspan="1">Baseline</td>
<td align="left" colspan="1" rowspan="1">4.1 (3.2, 5.0)</td>
<td align="left" colspan="1" rowspan="1">93</td>
<td align="left" colspan="1" rowspan="1">3.7 (3.0, 4.5)</td>
<td align="left" colspan="1" rowspan="1">526</td>
<td align="left" colspan="1" rowspan="1">0.0017</td>
<td align="left" colspan="1" rowspan="1">Baseline</td>
<td align="left" colspan="1" rowspan="1">3.7 (3.1, 4.5)</td>
<td align="left" colspan="1" rowspan="1">444</td>
<td align="left" colspan="1" rowspan="1">3.7 (3.1, 4.6)</td>
<td align="left" colspan="1" rowspan="1">630</td>
<td align="left" colspan="1" rowspan="1">0.9738</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Change at Week 240</td>
<td align="left" colspan="1" rowspan="1">–0.3 (–0.9, 0.4)</td>
<td align="left" colspan="1" rowspan="1">65</td>
<td align="left" colspan="1" rowspan="1">0.1 (–0.4, 0.6)</td>
<td align="left" colspan="1" rowspan="1">345</td>
<td align="left" colspan="1" rowspan="1">0.0044</td>
<td align="left" colspan="1" rowspan="1">Change at Week 48</td>
<td align="left" colspan="1" rowspan="1">–0.1 (–0.5, 0.4)</td>
<td align="left" colspan="1" rowspan="1">412</td>
<td align="left" colspan="1" rowspan="1">0.0 (–0.4, 0.3)</td>
<td align="left" colspan="1" rowspan="1">593</td>
<td align="left" colspan="1" rowspan="1">0.933</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">
<p>Median eGFR, mL/min</p>
<p>(Q1, Q3)<sup>b</sup></p>
</td>
<td align="left" colspan="1" rowspan="1">Baseline</td>
<td align="left" colspan="1" rowspan="1">99.2 (83.6, 114.0)</td>
<td align="left" colspan="1" rowspan="1">96</td>
<td align="left" colspan="1" rowspan="1">126.3 (108.5, 146.8)</td>
<td align="left" colspan="1" rowspan="1">538</td>
<td align="left" colspan="1" rowspan="1">&lt; 0.0001</td>
<td align="left" colspan="1" rowspan="1">Baseline</td>
<td align="left" colspan="1" rowspan="1">88.6 (75.5, 105.4)</td>
<td align="left" colspan="1" rowspan="1">450</td>
<td align="left" colspan="1" rowspan="1">107.9 (93.0, 126.6)</td>
<td align="left" colspan="1" rowspan="1">640</td>
<td align="left" colspan="1" rowspan="1">&lt; 0.0001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Change at Week 240</td>
<td align="left" colspan="1" rowspan="1">–10.5 (–19.6, 2.4)</td>
<td align="left" colspan="1" rowspan="1">67</td>
<td align="left" colspan="1" rowspan="1">–7.7 (–19.4, 3.0)</td>
<td align="left" colspan="1" rowspan="1">363</td>
<td align="left" colspan="1" rowspan="1">0.3003</td>
<td align="left" colspan="1" rowspan="1">Change at Week 48</td>
<td align="left" colspan="1" rowspan="1">–0.9 (–8.1, 5.8)</td>
<td align="left" colspan="1" rowspan="1">422</td>
<td align="left" colspan="1" rowspan="1">–1.0 (–9.6, 8.4)</td>
<td align="left" colspan="1" rowspan="1">603</td>
<td align="left" colspan="1" rowspan="1">0.9223</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p51">
<p>Baseline value was defined as the last nonmissing value obtained on or prior to the first dose of B/F/TAF. <em>P</em> values were from the 2-sided Wilcoxon rank sum test</p>
<p><em>B/F/TAF</em> Bictegravir/emtricitabine/tenofovir alafenamide, <em>eGFR</em> Estimated glomerular filtration rate, <em>HDL</em> High-density lipoprotein, <em>Q</em> Quartil, TC Total cholesterol</p>
<p><sup>a</sup>Only laboratory measurements under fasting conditions are summarized. <sup>b</sup>By Cockcroft-Gault equation</p>
</div></div></section><p id="Par51">Change from baseline in fasting lipid parameters, specifically the TC: HDL ratio, was assessed across both age groups. At Week 240 in the treatment-naïve cohort, the median (Q1, Q3) change from baseline in TC: HDL ratio was − 0.3 (–0.9, 0.4) for participants ≥ 50 years of age and 0.1 (–0.4, 0.6) for those &lt; 50 years of age. At Week 48 in the virologically suppressed cohort, change in the TC: HDL ratio was minimal, with a median (Q1, Q3) change of − 0.1 (–0.5, 0.4) for participants ≥ 50 years of age and 0.0 (–0.4, 0.3) for those &lt; 50 years of age (Table <a href="#Tab3" class="usa-link">3</a>). Additionally, the proportion of participants who initiated lipid-modifying agents during the study was higher among those ≥ 50 years of age compared with those &lt; 50 years of age (5.3% vs. 0.8%, respectively; <em>P</em> &lt; 0.0001).</p>
<p id="Par52">Change from baseline in eGFR was similar across age groups in both the treatment-naïve and virologically suppressed cohorts. At Week 240 in the treatment-naïve cohort, the median (Q1, Q3) change in eGFR from baseline was − 10.5 mL/min (–19.6, 2.4) for participants ≥ 50 years of age and − 7.7 mL/min (–19.4, 3.0) for those &lt; 50 years of age, with no statistically significant difference between age groups (<em>P</em> = 0.30). At Week 48 in the virologically suppressed cohort, the median (Q1, Q3) change in eGFR was − 0.9 mL/min (–8.1, 5.8) for participants ≥ 50 years of age and − 1.0 mL/min (–9.6, 8.4) for those &lt; 50 years of age (<em>P</em> = 0.92), indicating minimal change and no significant difference across age groups (Table <a href="#Tab3" class="usa-link">3</a>).</p>
<p id="Par53">Change from baseline in BMD was minimal and similar between age groups in both cohorts. At Week 240 in the treatment-naïve cohort, the mean (SD) percent change in hip BMD was 0.3% (3.26%) for participants ≥ 50 years of age and − 0.4% (5.80%) for those &lt; 50 years of age, while mean (SD) percent change in spine BMD was 1.3% (5.64%) and − 0.9% (4.95%), respectively. At Week 48 in the virologically suppressed cohort, the mean (SD) percent change in hip BMD was 0.2% (2.43%) for participants ≥ 50 years of age and 0.1% (2.03%) for those &lt; 50 years of age; mean percent change in spine BMD increased by 0.5% (3.52%) and 0.8% (2.78%), respectively. No significant difference was observed between age groups in either cohort (Fig. <a href="#Fig2" class="usa-link">2</a>).</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374459_12879_2025_11476_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6ac/12374459/a241929379ed/12879_2025_11476_Fig2_HTML.jpg" loading="lazy" id="d33e1273" height="843" width="669" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Percent change from baseline in BMD in the treatment-naïve (<strong>A</strong>) and virologically suppressed (<strong>B</strong>) cohorts. BMD, bone mineral density; SD, standard deviation. <strong>A</strong> Treatment-naïve cohort: mean percent change in hip and spine BMD from baseline to Week 240 in participants ≥50 years of age and &lt;50 years of age. <strong>B</strong> Virologically suppressed cohort: mean percent change in hip and spine BMD from baseline to Week 48 in participants≥50 years of age and &lt;50 years of age</p></figcaption></figure></section><section id="Sec12"><h3 class="pmc_sec_title">Other safety outcomes</h3>
<p id="Par55">In the treatment-naïve cohort, TEAEs were reported by 93.8% of participants ≥ 50 years of age and by 95.5% of those &lt; 50 years of age, with study drug–related TEAEs in 26.0% and 28.4% of participants, respectively. Grade 3 or 4 TEAEs affected 31.3% of participants ≥ 50 years of age and 19.0% of those &lt; 50 years of age, with serious TEAEs in 34.4% and 19.1% of participants, respectively. Discontinuation due to TEAEs occurred in 4.2% and 1.1% of participants in the ≥ 50 and &lt; 50 years of age groups, respectively, with 6 deaths (6.3%) among those ≥ 50 years of age and 2 deaths (0.4%) among those &lt; 50 years of age. In the virologically suppressed cohort, TEAEs were observed in 78.7% of participants ≥ 50 years of age and in 77.2% of those &lt; 50 years of age, with study drug–related TEAEs in 12.9% and 12.5% of each group, respectively. Grade 3 or 4 TEAEs were seen in 7.3% and 4.7% of participants ≥ 50 and &lt; 50 years of age, respectively, with serious TEAEs in 8.7% and 4.7%. Discontinuation due to TEAEs occurred in 1.8% of participants ≥ 50 years of age and 0.9% of those &lt; 50 years of age, with 2 deaths reported in each age group (0.4% and 0.3%, respectively; Table <a href="#Tab4" class="usa-link">4</a>).</p>
<section class="tw xbox font-sm" id="Tab4"><h4 class="obj_head">Table 4.</h4>
<div class="caption p"><p>TEAEs</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="3" colspan="1">TEAE, <em>n</em> (%)</th>
<th align="left" colspan="2" rowspan="1">Treatment-naïve cohort</th>
<th align="left" colspan="2" rowspan="1">Virologically suppressed cohort</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">≥ 50 years of age</th>
<th align="left" colspan="1" rowspan="1">&lt; 50 years of age</th>
<th align="left" colspan="1" rowspan="1">≥ 50 years of age</th>
<th align="left" colspan="1" rowspan="1">&lt; 50 years of age</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">
<em>n</em> = 96</th>
<th align="left" colspan="1" rowspan="1">
<em>n</em> = 538</th>
<th align="left" colspan="1" rowspan="1">
<em>n</em> = 450</th>
<th align="left" colspan="1" rowspan="1">
<em>n</em> = 640</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Any TEAE <sup>a</sup>
</td>
<td align="left" colspan="1" rowspan="1">90 (93.8)</td>
<td align="left" colspan="1" rowspan="1">514 (95.5)</td>
<td align="left" colspan="1" rowspan="1">354 (78.7)</td>
<td align="left" colspan="1" rowspan="1">494 (77.2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Study drug–related TEAEs</td>
<td align="left" colspan="1" rowspan="1">25 (26.0)</td>
<td align="left" colspan="1" rowspan="1">153 (28.4)</td>
<td align="left" colspan="1" rowspan="1">58 (12.9)</td>
<td align="left" colspan="1" rowspan="1">80 (12.5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Any grade 3 or 4 TEAEs</td>
<td align="left" colspan="1" rowspan="1">30 (31.3)</td>
<td align="left" colspan="1" rowspan="1">102 (19.0)</td>
<td align="left" colspan="1" rowspan="1">33 (7.3)</td>
<td align="left" colspan="1" rowspan="1">30 (4.7)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Study drug–related grade 3 or 4 TEAEs</td>
<td align="left" colspan="1" rowspan="1">4 (4.2)<sup>b</sup>
</td>
<td align="left" colspan="1" rowspan="1">5 (0.9)<sup>c</sup>
</td>
<td align="left" colspan="1" rowspan="1">3 (0.7)</td>
<td align="left" colspan="1" rowspan="1">4 (0.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Any serious TEAE</td>
<td align="left" colspan="1" rowspan="1">33 (34.4)</td>
<td align="left" colspan="1" rowspan="1">103 (19.1)</td>
<td align="left" colspan="1" rowspan="1">39 (8.7)</td>
<td align="left" colspan="1" rowspan="1">30 (4.7)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Study drug–related serious TEAEs</td>
<td align="left" colspan="1" rowspan="1">2 (2.1)<sup>d</sup>
</td>
<td align="left" colspan="1" rowspan="1">3 (0.6)<sup>e</sup>
</td>
<td align="left" colspan="1" rowspan="1">1 (0.2)</td>
<td align="left" colspan="1" rowspan="1">1 (0.2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Study drug discontinuation due to TEAEs</td>
<td align="left" colspan="1" rowspan="1">4 (4.2)<sup>f</sup>
</td>
<td align="left" colspan="1" rowspan="1">6 (1.1)<sup>g</sup>
</td>
<td align="left" colspan="1" rowspan="1">8 (1.8)</td>
<td align="left" colspan="1" rowspan="1">6 (0.9)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Death</td>
<td align="left" colspan="1" rowspan="1">6 (6.3)<sup>h</sup>
</td>
<td align="left" colspan="1" rowspan="1">2 (0.4)<sup>i</sup>
</td>
<td align="left" colspan="1" rowspan="1">2 (0.4)</td>
<td align="left" colspan="1" rowspan="1">2 (0.3)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p62">
<p><em>COVID</em> Coronavirus, <em>TEAE</em> Treatment-emergent adverse event</p>
<p><sup>a</sup>Safety through the end of the study. <sup>b</sup>Due to atrial flutter, dizziness, and acute pancreatitis (in the same participant); and abdominal pain, atypical chest pain, and elevated liver enzyme levels (<em>n</em> = 1 each). <sup>c</sup>Due to abdominal distention, diarrhea, generalized tonic-clonic seizure, osteoporosis, and suicide attempt (<em>n</em> = 1 each). <sup>d</sup>Due to atrial flutter, acute pancreatitis, and dizziness (in the same participant); and chest pain (<em>n</em> = 1). <sup>e</sup>Due to generalized tonic-clonic seizure, spontaneous abortion, and suicide attempt (<em>n</em> = 1 each). <sup>f</sup>Due to cardiac arrest, chest pain, COVID, and obesity (<em>n</em> = 1 each). <sup>g</sup>Due to abdominal distension, dyspepsia, toxicity due to various agents, intervertebral discitis, and tension headache (<em>n</em> = 1 each). <sup>h</sup>Due to cardiac arrest (<em>n</em> = 2) and hypertensive heart disease with congestive heart failure, poorly differentiated gastric adenocarcinoma, COVID, and drug toxicity (<em>n</em> = 1 each). <sup>i</sup>Due to hemorrhagic hypovolemia (self-inflicted) and an unknown cause (<em>n</em> = 1 each). For the treatment-naïve cohort, data on TEAEs were collected through Week 240 (end of study). For the virologically suppressed cohort, data on TEAEs were collected through Week 48</p>
</div></div></section></section><section id="Sec13"><h3 class="pmc_sec_title">Treatment-emergent diabetes and hypertension</h3>
<p id="Par57">Treatment-emergent (events that occur while on study) diabetes and hypertension through Week 240 for the treatment-naïve cohort and through Week 48 for the virologically suppressed cohort are shown in Table <a href="#Tab5" class="usa-link">5</a>. From baseline to Week 240, treatment-emergent diabetes was observed in 5.1% of participants ≥ 50 years of age and 1.7% of those &lt; 50 years of age (<em>P</em> = 0.08). Treatment-emergent hypertension was reported in 19.6% of participants ≥ 50 years of age and 12.5% of those &lt; 50 years of age (<em>P</em> = 0.19). At Week 48 in the virologically suppressed cohort, the incidence of treatment-emergent diabetes was 1.1% in participants ≥ 50 years of age and 1.3% in those &lt; 50 years of age (<em>P</em> = 1.00), while treatment-emergent hypertension was observed in 5.2% of participants ≥ 50 years of age and 2.6% of those &lt; 50 years of age (<em>P</em> = 0.07). No significant difference in rates of treatment-emergent diabetes or hypertension was found between age groups in either cohort (Table <a href="#Tab5" class="usa-link">5</a>).</p>
<section class="tw xbox font-sm" id="Tab5"><h4 class="obj_head">Table 5.</h4>
<div class="caption p"><p>Treatment-emergent diabetes and hypertension</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="4" colspan="1"></th>
<th align="left" colspan="4" rowspan="1">Treatment-naïve cohort</th>
<th align="left" rowspan="4" colspan="1">
<em>P</em> value</th>
<th align="left" colspan="4" rowspan="1">Virologically suppressed cohort</th>
<th align="left" rowspan="4" colspan="1">
<em>P</em> value<sup>b</sup>
</th>
</tr>
<tr>
<th align="left" colspan="2" rowspan="1">≥ 50 years of age</th>
<th align="left" colspan="2" rowspan="1">&lt; 50 years of age</th>
<th align="left" colspan="2" rowspan="1">≥ 50 years of age</th>
<th align="left" colspan="2" rowspan="1">&lt; 50 years of age</th>
</tr>
<tr>
<th align="left" colspan="2" rowspan="1">
<em>n</em> = 538</th>
<th align="left" colspan="2" rowspan="1">
<em>n</em> = 450</th>
<th align="left" colspan="2" rowspan="1">
<em>n</em> = 96</th>
<th align="left" colspan="2" rowspan="1">
<em>n</em> = 538</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">
<em>n</em> (%)</th>
<th align="left" colspan="1" rowspan="1">Participants with available data, <em>n</em>
</th>
<th align="left" colspan="1" rowspan="1">
<em>n</em> (%)</th>
<th align="left" colspan="1" rowspan="1">Participants with available data, <em>n</em>
</th>
<th align="left" colspan="1" rowspan="1">
<em>n</em> (%)</th>
<th align="left" colspan="1" rowspan="1">Participants with available data, <em>n</em>
</th>
<th align="left" colspan="1" rowspan="1">
<em>n</em> (%)</th>
<th align="left" colspan="1" rowspan="1">Participants with available data, <em>n</em>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Treatment-emergent diabetes<sup>a</sup>
</td>
<td align="center" colspan="1" rowspan="1">4 (5.1)</td>
<td align="center" colspan="1" rowspan="1">78</td>
<td align="center" colspan="1" rowspan="1">9 (1.7)</td>
<td align="center" colspan="1" rowspan="1">515</td>
<td align="center" colspan="1" rowspan="1">0.08</td>
<td align="center" colspan="1" rowspan="1">4 (1.1)</td>
<td align="center" colspan="1" rowspan="1">374</td>
<td align="center" colspan="1" rowspan="1">8 (1.3)</td>
<td align="center" colspan="1" rowspan="1">602</td>
<td align="center" colspan="1" rowspan="1">1.00</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Treatment-emergent hypertension <sup>a</sup>
</td>
<td align="center" colspan="1" rowspan="1">10 (19.6)</td>
<td align="center" colspan="1" rowspan="1">51</td>
<td align="center" colspan="1" rowspan="1">61 (12.5)</td>
<td align="center" colspan="1" rowspan="1">489</td>
<td align="center" colspan="1" rowspan="1">0.19</td>
<td align="center" colspan="1" rowspan="1">14 (5.2)</td>
<td align="center" colspan="1" rowspan="1">268</td>
<td align="center" colspan="1" rowspan="1">14 (2.6)</td>
<td align="center" colspan="1" rowspan="1">529</td>
<td align="center" colspan="1" rowspan="1">0.07</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p67">
<p>For the treatment-naïve cohort, treatment-emergent diabetes and hypertension data were collected through Week 240 (end of study). For the virologically suppressed cohort, treatment-emergent diabetes and hypertension data were collected through Week 48</p>
<p><sup>a</sup>Participants with a medical history of diabetes and hypertension were excluded. <sup>b</sup>Calculated by Fisher exact test</p>
</div></div></section></section></section><section id="Sec14"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par59">This analysis demonstrated that B/F/TAF offers durable efficacy and a favorable safety profile for PWH ≥ 50 years of age, making it as a suitable option for long-term treatment in this growing population. High rates of virologic suppression were maintained in both the treatment-naïve and virologically suppressed cohorts, with no significant difference between older and younger participants. These findings highlight B/F/TAF’s ability to provide sustained virologic control while addressing the unique treatment needs of older adults. Notably, adherence rates remained high among older participants [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>, <a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>], reinforcing the regimen’s practicality as a once-daily, single-tablet regimen that is well-suited to complex patient needs. This analysis includes older PWH (≥ 50 years of age), with a median age of 55 years in the treatment-naïve cohort and 56 years in the virologically suppressed cohort and provides valuable insights into baseline characteristics and treatment outcomes. The inclusion of older PWH helps address a critical gap in understanding the efficacy and safety of B/F/TAF among this population.</p>
<p id="Par60">B/F/TAF has previously demonstrated durable, long-term viral suppression in diverse populations, including in those with significant comorbidities [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. Its high barrier to resistance and flexibility in adherence make it particularly well-suited for older adults, especially those who may face additional adherence challenges due to polypharmacy or cognitive changes [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>, <a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>]. In the treatment-naïve cohort of this study, B/F/TAF achieved high rates of viral suppression, even among participants with lower adherence over a prolonged follow-up period, highlighting the regimen’s durability in observational settings where suboptimal adherence often occurs. The low incidence of drug-related adverse events further supports the regimen’s suitability for older PWH, who may have an increased risk of adverse events due to comorbidities and concomitant medications.</p>
<p id="Par61">Immunologic outcomes were similarly robust across age groups, with older participants demonstrating CD4 T-cell gains that were comparable with those of younger participants. This is especially relevant for older PWH, who are at a greater risk for infections and other immune-related complications due to age-associated immune decline.</p>
<p id="Par62">Safety outcomes were favorable overall, with low study drug discontinuation due to TEAEs and study drug related grade 3 or 4 TEAEs. Although serious adverse events were more frequent among older participants, most were not drug-related, reflecting the greater comorbidity burden in this population. Importantly, B/F/TAF had minimal impact on weight, lipid profiles, and other metabolic markers, including diabetes mellitus and hypertension rates, in both the treatment-naïve and virologically suppressed cohorts, which is particularly beneficial for older adults who are at an elevated baseline risk for cardiovascular conditions.</p>
<p id="Par63">Dyslipidemia is a recognized contributor to cardiovascular risk in PWH &gt; 50 years of age, and certain ART regimens have been linked to adverse effects on lipid profiles [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>, <a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. In contrast, B/F/TAF is considered metabolically neutral and is recommended as a first-line treatment for HIV-1, with a favorable safety profile for individuals at an elevated cardiovascular risk. In this study, the higher proportion of participants ≥ 50 years of age who initiated lipid-modifying agents likely reflects their increased baseline cardiovascular risk. Our analysis suggests that participants with adverse baseline lipid levels may benefit most from switching to B/F/TAF from prior regimens that include abacavir or boosted protease inhibitors, underscoring its suitability for older PWH who have dyslipidemia and cardiovascular concerns [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>, <a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]. Notably, recent guideline updates informed by the REPRIEVE trial emphasize the importance of comprehensive cardiovascular risk management in PWH, which includes lipid-modifying therapy as an essential component [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>, <a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>].</p>
<p id="Par64">Renal and bone safety are also critical considerations in the long-term management of PWH, particularly in older adults at risk for age-related declines in renal function and bone health [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>–<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>, <a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. Chronic kidney disease is more common in PWH ≥ 50 years of age; yet, in this analysis, B/F/TAF demonstrated minimal nephrotoxic impact, with changes in eGFR that were comparable across age groups. These changes showed minimal declines, with no significant differences observed between participants ≥ 50 and &lt; 50 years of age in both the treatment-naïve and virologically suppressed cohorts. This is consistent with the known inhibition of organic cation transporter–2 and tubular creatinine secretion by bictegravir, as previously reported. B/F/TAF also exhibited a neutral effect on BMD, an important finding given that HIV infection and some ART regimens have been associated with an increased risk of osteoporosis and fractures, especially in older adults [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>, <a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]. BMD changes were minimal in both the hip and spine across both age groups.</p>
<p id="Par65">In addition to renal and bone safety, metabolic outcomes were also evaluated, such as the emergence of type 2 diabetes mellitus and hypertension during the study. The incidence rate of both conditions was low and comparable across age groups, with a modestly higher occurrence in older, treatment-naïve participants but no significant difference in the virologically suppressed cohort. These findings underscore B/F/TAF’s favorable metabolic profile, as it does not appear to exacerbate the risk of dysglycemia or hypertension, especially in virologically suppressed PWH.</p>
<p id="Par66">This study has limitations, including the underrepresentation of participants &gt; 65 years of age (particularly in the treatment-naïve group, where only 5 individuals were included) and the lack of data for those &gt; 80 years of age, which limits the ability to fully assess the safety profile in older age groups. Additionally, the open-label design of Studies 1878 and 1961, as well as the underrepresentation of participants with advanced immunosuppression and women, may affect the generalizability of the findings. Greater efforts to enroll women and other underserved populations in large phase 3 trials are needed to ensure that study results are broadly applicable. Nevertheless, the results align well with prior randomized trials of B/F/TAF, supporting the applicability of these findings to a broader population within the studied age range.</p>
<p id="Par67">In conclusion, B/F/TAF demonstrated sustained efficacy, a favorable safety profile, and high tolerability in PWH ≥ 50 years of age, including in both the treatment-naïve and virologically suppressed cohorts, underscoring its value as an optimal treatment option for managing HIV in aging populations. These findings contribute to the growing evidence that supports B/F/TAF as an effective ART that addresses both HIV-related needs and the additional health complexities faced by older adults.</p></section><section id="Sec15"><h2 class="pmc_sec_title">Supplementary Information</h2>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12374459/bin/12879_2025_11476_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1.</a><sup> (418.8KB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We thank all participants and investigators who were involved in the study. Medical writing support was provided by Bill Wang, PhD, of Gilead Sciences, Inc., with editorial support provided by Lumanity Communications Inc. (Yardley, PA, USA) and funded by Gilead Sciences, Inc.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>ART</dt>
<dd><p id="Par5">Antiretroviral therapy</p></dd>
<dt>B/F/TAF</dt>
<dd><p id="Par6">Bictegravir/emtricitabine/tenofovir alafenamide</p></dd>
<dt>BMD</dt>
<dd><p id="Par7">Bone mineral density</p></dd>
<dt>CI</dt>
<dd><p id="Par8">Confidence interval</p></dd>
<dt>eGFR</dt>
<dd><p id="Par9">Estimated glomerular filtration rate</p></dd>
<dt>FDA</dt>
<dd><p id="Par10">US Food and Administration</p></dd>
<dt>HDL</dt>
<dd><p id="Par11">High-density lipoprotein</p></dd>
<dt>HIV</dt>
<dd><p id="Par12">Human immunodeficiency virus</p></dd>
<dt>LDL</dt>
<dd><p id="Par13">Low-density lipoprotein</p></dd>
<dt>LSMD</dt>
<dd><p id="Par14">Least squares mean difference</p></dd>
<dt>M= E</dt>
<dd><p id="Par15">Missing= excluded</p></dd>
<dt>M= F</dt>
<dd><p id="Par16">Missing= failure</p></dd>
<dt>PWH</dt>
<dd><p id="Par17">People with HIV</p></dd>
<dt>Q</dt>
<dd><p id="Par18">Quartile</p></dd>
<dt>SD</dt>
<dd><p id="Par19">Standard deviation</p></dd>
<dt>SMQ</dt>
<dd><p id="Par20">Standardized<em>Medical Dictionary for Regulatory Activities</em> query</p></dd>
<dt>TAF</dt>
<dd><p id="Par21">Tenofovir alafenamide</p></dd>
<dt>TC</dt>
<dd><p id="Par22">Total cholesterol</p></dd>
<dt>TDF</dt>
<dd><p id="Par23">Tenofovir disoproxil fumarate</p></dd>
<dt>TEAE</dt>
<dd><p id="Par24">Treatment-emergent adverse event</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Authors’ contributions</h2>
<p>All authors contributed to the study conception and design. Material preparation, data collection, and analyses were performed by SKG, PNK, and JKR. Tables and figures were prepared by all of the authors. The first draft of the manuscript was written by the authors, and all authors commented on previous versions of the manuscript. All authors reviewed the final version. All authors read and approved the final manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This study was funded by Gilead Sciences, Inc.</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>Gilead Sciences shares anonymized individual participant data upon request or as required by law or regulation with qualified external researchers based on submitted curriculum vitae that reflect no conflicts of interest. The request proposal must also include a statistician. Approval of such requests is at Gilead Science’s discretion and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data. Data requests should be sent to datasharing@gilead.com.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par68">All studies were conducted in accordance with the Declaration of Helsinki and approved by the following ethics committees: Commissie voor Medische Ethiek, Universitair Ziekenhuis Gent, Belgium; CPP Sud Mediterranee V, CHU de NICE - Hopital de CIMIEZ, France; Ethikkommission des Fachbereichs Medizin der Johann Wolfgang Goethe-Universität Frankfurt am Main, Germany; Comitato Etico, Istituto Nazionale per le Malattie Infettive “Lazzaro Spallanzani” IRCCS, Italy; Comitato Etico, IRCCS Ospedale S. Raffaele di Milano, Italy; Comitato Etico della Provincia di Bergamo, ASST Papa Giovanni XXIII, Italy; CEIC Hospital Universitari de Bellvitge, Spain; National Research Ethics Service Committee London - Hampstead Research Ethics Committee, United Kingdom; Sunnybrook Research Ethics Board, Sunnybrook Health Sciences Centre, Canada; Ottawa Health Science Network Research Ethics Board, Canada; Centre for Applied Ethics/MUHC Research Ethics Board, McGill University Health Centre, Canada; Advarra Institutional Review Board, United States; Prisma Health Institutional Review Board, United States; Institutional Review Board at Dallas, University of Texas Southwestern Medical Center, United States; Duke University Health System Institutional Review Board, United States; Bellberry Human Research Ethics Committee, Australia; St Vincent’s Hospital Human Research Ethics Committee, Australia. Institutional review boards at each site granted ethical approval, and all participants provided written informed consent.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par69">Not applicable.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par70">CMK reports grants or contracts from Janssen. SKG reports grants or contracts from the National Institutes of Health and ViiV Healthcare; consulting fees from Gilead Sciences, Inc., and ViiV Healthcare. PNK reports grants or contracts from ViiV Healthcare, Gilead Science, Inc., Merck, and Theratechnologies; consulting fees from ViiV Healthcare, Gilead Sciences, Inc., and Merck; participation on a data safety monitoring board or advisory board from ViiV Healthcare, Gilead Sciences, Inc., and Merck; stock or stock options from Merck, Pfizer, Gilead Sciences, Inc., Johnson &amp; Johnson, GSK, and Moderna. ARW, BG-P, HL, and JTH are employees and stockholders of Gilead Sciences, Inc. JKR reports grants or contracts from Gilead Sciences Inc.; consulting fees from AbbVie and Boehringer Ingelheim; payment or honoraria from Gilead Sciences Inc., Janssen, MSD, and ViiV Healthcare; participation on a data safety monitoring board or advisory board from Berlin Cures; other leadership or fiduciary role for EuroTESt.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher’s Note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18(4):256–66.
</cite> [<a href="https://doi.org/10.1111/hiv.12421" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27578404/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Teeraananchai%20S,%20Kerr%20SJ,%20Amin%20J,%20Ruxrungtham%20K,%20Law%20MG.%20Life%20expectancy%20of%20HIV-positive%20people%20after%20starting%20combination%20antiretroviral%20therapy:%20a%20meta-analysis.%20HIV%20Med.%202017;18(4):256%E2%80%9366." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Xiao Y, Sun X, Tang S, Zhou Y, Peng Z, Wu J, et al. Personalized life expectancy and treatment benefit index of antiretroviral therapy. Theor Biol Med Model. 2017;14(1):1.
</cite> [<a href="https://doi.org/10.1186/s12976-016-0047-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5242026/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28100241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xiao%20Y,%20Sun%20X,%20Tang%20S,%20Zhou%20Y,%20Peng%20Z,%20Wu%20J,%20et%20al.%20Personalized%20life%20expectancy%20and%20treatment%20benefit%20index%20of%20antiretroviral%20therapy.%20Theor%20Biol%20Med%20Model.%202017;14(1):1." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>UNAIDS. 2023 UNAIDS global AIDS update. <a href="https://thepath.unaids.org/wp-content/themes/unaids2023/assets/files/2023_report.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://thepath.unaids.org/wp-content/themes/unaids2023/assets/files/2023_report.pdf</a>. Accessed 30 Jan 2025.</cite>
</li>
<li id="CR4">
<span class="label">4.</span><cite>Autenrieth CS, Beck EJ, Stelzle D, Mallouris C, Mahy M, Ghys P. Global and regional trends of people living with HIV aged 50 and over: estimates and projections for 2000–2020. PLoS One. 2018;13(11):e0207005.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0207005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6264840/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30496302/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Autenrieth%20CS,%20Beck%20EJ,%20Stelzle%20D,%20Mallouris%20C,%20Mahy%20M,%20Ghys%20P.%20Global%20and%20regional%20trends%20of%20people%20living%20with%20HIV%20aged%2050%20and%20over:%20estimates%20and%20projections%20for%202000%E2%80%932020.%20PLoS%20One.%202018;13(11):e0207005." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, et al. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infect Dis Ther. 2018;7(2):183–95.
</cite> [<a href="https://doi.org/10.1007/s40121-018-0201-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5986685/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29761330/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chawla%20A,%20Wang%20C,%20Patton%20C,%20Murray%20M,%20Punekar%20Y,%20de%20Ruiter%20A,%20et%20al.%20A%20review%20of%20long-term%20toxicity%20of%20antiretroviral%20treatment%20regimens%20and%20implications%20for%20an%20aging%20population.%20Infect%20Dis%20Ther.%202018;7(2):183%E2%80%9395." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Erlandson KM, Karris MY. HIV and aging: reconsidering the approach to management of comorbidities. Infect Dis Clin North Am. 2019;33(3):769–86.
</cite> [<a href="https://doi.org/10.1016/j.idc.2019.04.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6690376/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31395144/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Erlandson%20KM,%20Karris%20MY.%20HIV%20and%20aging:%20reconsidering%20the%20approach%20to%20management%20of%20comorbidities.%20Infect%20Dis%20Clin%20North%20Am.%202019;33(3):769%E2%80%9386." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Kaplan-Lewis E, Aberg JA, Lee M. Aging with HIV in the ART era. Semin Diagn Pathol. 2017;34(4):384–97.
</cite> [<a href="https://doi.org/10.1053/j.semdp.2017.04.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28552209/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kaplan-Lewis%20E,%20Aberg%20JA,%20Lee%20M.%20Aging%20with%20HIV%20in%20the%20ART%20era.%20Semin%20Diagn%20Pathol.%202017;34(4):384%E2%80%9397." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Roomaney RA, van Wyk B, van Pillay- Wyk V. Aging with HIV: increased risk of HIV comorbidities in older adults. Int J Environ Res Public Health. 2022. 10.3390/ijerph19042359.
</cite> [<a href="https://doi.org/10.3390/ijerph19042359" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8872228/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35206544/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Roomaney%20RA,%20van%20Wyk%20B,%20van%20Pillay-%20Wyk%20V.%20Aging%20with%20HIV:%20increased%20risk%20of%20HIV%20comorbidities%20in%20older%20adults.%20Int%20J%20Environ%20Res%20Public%20Health.%202022.%2010.3390/ijerph19042359." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Burrowes SAB, Zisman E, Fantry LE, Bui Q, Wu A, Sorkin J, et al. Changes in atherosclerotic cardiovascular disease risk scores in a predominantly black cohort with HIV and associated comorbidities: a preliminary study. Cardiol Published Online August. 2024;6. 10.1159/000540526.</cite> [<a href="https://doi.org/10.1159/000540526" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11799351/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39106839/" class="usa-link">PubMed</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Gallant J, Hsue PY, Shreay S, Meyer N. Comorbidities among US patients with prevalent HIV infection-a trend analysis. J Infect Dis. 2017;216(12):1525–33.
</cite> [<a href="https://doi.org/10.1093/infdis/jix518" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29253205/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gallant%20J,%20Hsue%20PY,%20Shreay%20S,%20Meyer%20N.%20Comorbidities%20among%20US%20patients%20with%20prevalent%20HIV%20infection-a%20trend%20analysis.%20J%20Infect%20Dis.%202017;216(12):1525%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Masters MC, Tassiopoulos K, Bao Y, Wu K, Koletar SL, Rubin LH, et al. Risk factors for progression from prediabetes to diabetes among older people with HIV. AIDS. 2024;38(12):1740–8.
</cite> [<a href="https://doi.org/10.1097/QAD.0000000000003970" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11365760/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38923420/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Masters%20MC,%20Tassiopoulos%20K,%20Bao%20Y,%20Wu%20K,%20Koletar%20SL,%20Rubin%20LH,%20et%20al.%20Risk%20factors%20for%20progression%20from%20prediabetes%20to%20diabetes%20among%20older%20people%20with%20HIV.%20AIDS.%202024;38(12):1740%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>McCutcheon K, Nqebelele U, Murray L, Thomas TS, Mpanya D, Tsabedze N. Cardiac and renal comorbidities in aging people living with HIV. Circ Res. 2024;134(11):1636–60.
</cite> [<a href="https://doi.org/10.1161/CIRCRESAHA.124.323948" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11122746/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38781295/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?McCutcheon%20K,%20Nqebelele%20U,%20Murray%20L,%20Thomas%20TS,%20Mpanya%20D,%20Tsabedze%20N.%20Cardiac%20and%20renal%20comorbidities%20in%20aging%20people%20living%20with%20HIV.%20Circ%20Res.%202024;134(11):1636%E2%80%9360." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Nadkarni GN, Konstantinidis I, Wyatt CM. HIV and the aging kidney. Curr Opin HIV AIDS. 2014;9(4):340–5.
</cite> [<a href="https://doi.org/10.1097/COH.0000000000000067" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24824884/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nadkarni%20GN,%20Konstantinidis%20I,%20Wyatt%20CM.%20HIV%20and%20the%20aging%20kidney.%20Curr%20Opin%20HIV%20AIDS.%202014;9(4):340%E2%80%935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Schinas G, Schinas I, Ntampanlis G, Polyzou E, Gogos C, Akinosoglou K. Bone disease in HIV: need for early diagnosis and prevention. Life (Basel). 2024;14(4): 522.
</cite> [<a href="https://doi.org/10.3390/life14040522" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11051575/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38672792/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Schinas%20G,%20Schinas%20I,%20Ntampanlis%20G,%20Polyzou%20E,%20Gogos%20C,%20Akinosoglou%20K.%20Bone%20disease%20in%20HIV:%20need%20for%20early%20diagnosis%20and%20prevention.%20Life%20(Basel).%202024;14(4):%20522." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Skelton M, Callahan C, Levit M, Finn T, Kister K, Matsumura S, et al. Men with HIV have increased alveolar bone loss. BMC Oral Health. 2024;24(1): 1248.
</cite> [<a href="https://doi.org/10.1186/s12903-024-04989-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11490168/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39427141/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Skelton%20M,%20Callahan%20C,%20Levit%20M,%20Finn%20T,%20Kister%20K,%20Matsumura%20S,%20et%20al.%20Men%20with%20HIV%20have%20increased%20alveolar%20bone%20loss.%20BMC%20Oral%20Health.%202024;24(1):%201248." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, et al. Bictegravir, emtricitabine, and Tenofovir Alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063–72.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(17)32299-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28867497/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gallant%20J,%20Lazzarin%20A,%20Mills%20A,%20Orkin%20C,%20Podzamczer%20D,%20Tebas%20P,%20et%20al.%20Bictegravir,%20emtricitabine,%20and%20Tenofovir%20Alafenamide%20versus%20dolutegravir,%20abacavir,%20and%20lamivudine%20for%20initial%20treatment%20of%20HIV-1%20infection%20(GS-US-380-1489):%20a%20double-blind,%20multicentre,%20phase%203,%20randomised%20controlled%20non-inferiority%20trial.%20Lancet.%202017;390(10107):2063%E2%80%9372." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, et al. Bictegravir versus dolutegravir, each with emtricitabine and Tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017;4(4):e154–60.
</cite> [<a href="https://doi.org/10.1016/S2352-3018(17)30016-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28219610/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sax%20PE,%20DeJesus%20E,%20Crofoot%20G,%20Ward%20D,%20Benson%20P,%20Dretler%20R,%20et%20al.%20Bictegravir%20versus%20dolutegravir,%20each%20with%20emtricitabine%20and%20Tenofovir%20alafenamide,%20for%20initial%20treatment%20of%20HIV-1%20infection:%20a%20randomised,%20double-blind,%20phase%202%20trial.%20Lancet%20HIV.%202017;4(4):e154%E2%80%9360." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Wohl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, et al. Bictegravir combined with emtricitabine and Tenofovir Alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e355–63.
</cite> [<a href="https://doi.org/10.1016/S2352-3018(19)30077-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31068270/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wohl%20DA,%20Yazdanpanah%20Y,%20Baumgarten%20A,%20Clarke%20A,%20Thompson%20MA,%20Brinson%20C,%20et%20al.%20Bictegravir%20combined%20with%20emtricitabine%20and%20Tenofovir%20Alafenamide%20versus%20dolutegravir,%20abacavir,%20and%20lamivudine%20for%20initial%20treatment%20of%20HIV-1%20infection:%20week%2096%20results%20from%20a%20randomised,%20double-blind,%20multicentre,%20phase%203,%20non-inferiority%20trial.%20Lancet%20HIV.%202019;6(6):e355%E2%80%9363." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, et al. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine. 2023;59:101991.
</cite> [<a href="https://doi.org/10.1016/j.eclinm.2023.101991" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10186485/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37200995/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sax%20PE,%20Arribas%20JR,%20Orkin%20C,%20Lazzarin%20A,%20Pozniak%20A,%20DeJesus%20E,%20et%20al.%20Bictegravir/emtricitabine/tenofovir%20alafenamide%20as%20initial%20treatment%20for%20HIV-1:%20five-year%20follow-up%20from%20two%20randomized%20trials.%20EClinicalMedicine.%202023;59:101991." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Maggiolo F, Rizzardini G, Raffi F, Pulido F, Mateo-Garcia MG, Molina JM, et al. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing Tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and Tenofovir Alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial. Lancet HIV. 2019;6(10):e655–66.
</cite> [<a href="https://doi.org/10.1016/S2352-3018(19)30195-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31578954/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Maggiolo%20F,%20Rizzardini%20G,%20Raffi%20F,%20Pulido%20F,%20Mateo-Garcia%20MG,%20Molina%20JM,%20et%20al.%20Bone%20mineral%20density%20in%20virologically%20suppressed%20people%20aged%2060%20years%20or%20older%20with%20HIV-1%20switching%20from%20a%20regimen%20containing%20Tenofovir%20disoproxil%20fumarate%20to%20an%20elvitegravir,%20cobicistat,%20emtricitabine,%20and%20Tenofovir%20Alafenamide%20single-tablet%20regimen:%20a%20multicentre,%20open-label,%20phase%203b,%20randomised%20trial.%20Lancet%20HIV.%202019;6(10):e655%E2%80%9366." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019;33(9):1455–65.
</cite> [<a href="https://doi.org/10.1097/QAD.0000000000002223" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6635043/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30932951/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gupta%20SK,%20Post%20FA,%20Arribas%20JR,%20Eron%20JJ%20Jr,%20Wohl%20DA,%20Clarke%20AE,%20et%20al.%20Renal%20safety%20of%20tenofovir%20alafenamide%20vs.%20tenofovir%20disoproxil%20fumarate:%20a%20pooled%20analysis%20of%2026%20clinical%20trials.%20AIDS.%202019;33(9):1455%E2%80%9365." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(suppl 1):S19–25.
</cite> [<a href="https://doi.org/10.1097/00002030-200418001-00004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2886736/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15075494/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hinkin%20CH,%20Hardy%20DJ,%20Mason%20KI,%20Castellon%20SA,%20Durvasula%20RS,%20Lam%20MN,%20et%20al.%20Medication%20adherence%20in%20HIV-infected%20adults:%20effect%20of%20patient%20age,%20cognitive%20status,%20and%20substance%20abuse.%20AIDS.%202004;18(suppl%201):S19%E2%80%9325." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Ghidei L, Simone MJ, Salow MJ, Zimmerman KM, Paquin AM, Skarf LM, et al. Aging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individuals. Drugs Aging. 2013;30(10):809–19.
</cite> [<a href="https://doi.org/10.1007/s40266-013-0107-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3844933/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23959913/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ghidei%20L,%20Simone%20MJ,%20Salow%20MJ,%20Zimmerman%20KM,%20Paquin%20AM,%20Skarf%20LM,%20et%20al.%20Aging,%20antiretrovirals,%20and%20adherence:%20a%20meta%20analysis%20of%20adherence%20among%20older%20HIV-infected%20individuals.%20Drugs%20Aging.%202013;30(10):809%E2%80%9319." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Siefried KJ, Mao L, Cysique LA, Rule J, Giles ML, Smith DE, et al. Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy. AIDS. 2018;32(1):35–48.
</cite> [<a href="https://doi.org/10.1097/QAD.0000000000001685" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5732638/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29135584/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Siefried%20KJ,%20Mao%20L,%20Cysique%20LA,%20Rule%20J,%20Giles%20ML,%20Smith%20DE,%20et%20al.%20Concomitant%20medication%20polypharmacy,%20interactions%20and%20imperfect%20adherence%20are%20common%20in%20Australian%20adults%20on%20suppressive%20antiretroviral%20therapy.%20AIDS.%202018;32(1):35%E2%80%9348." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Acosta RK, Willkom M, Martin R, Chang S, Wei X, Garner W, et al. Resistance analysis of bictegravir-emtricitabine-tenofovir alafenamide in HIV-1 treatment-naive patients through 48 weeks. Antimicrob Agents Chemother. 2019;63(5):e02533-18.
</cite> [<a href="https://doi.org/10.1128/AAC.02533-18" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6496090/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30803969/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Acosta%20RK,%20Willkom%20M,%20Martin%20R,%20Chang%20S,%20Wei%20X,%20Garner%20W,%20et%20al.%20Resistance%20analysis%20of%20bictegravir-emtricitabine-tenofovir%20alafenamide%20in%20HIV-1%20treatment-naive%20patients%20through%2048%20weeks.%20Antimicrob%20Agents%20Chemother.%202019;63(5):e02533-18." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Ombeni W, Kamuhabwa AR. Lipid profile in HIV-infected patients using first-line antiretroviral drugs. J Int Assoc Provid AIDS Care. 2016;15(2):164–71.
</cite> [<a href="https://doi.org/10.1177/2325957415614642" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26514630/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ombeni%20W,%20Kamuhabwa%20AR.%20Lipid%20profile%20in%20HIV-infected%20patients%20using%20first-line%20antiretroviral%20drugs.%20J%20Int%20Assoc%20Provid%20AIDS%20Care.%202016;15(2):164%E2%80%9371." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Li X, Song X, Han Y, Qiu Z, Cao W, Li T. Risk factors and longitudinal changes of dyslipidemia among Chinese people living with HIV receiving antiretroviral therapy. BMC Infect Dis. 2023;23(1):598.
</cite> [<a href="https://doi.org/10.1186/s12879-023-08587-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10500758/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37705002/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20X,%20Song%20X,%20Han%20Y,%20Qiu%20Z,%20Cao%20W,%20Li%20T.%20Risk%20factors%20and%20longitudinal%20changes%20of%20dyslipidemia%20among%20Chinese%20people%20living%20with%20HIV%20receiving%20antiretroviral%20therapy.%20BMC%20Infect%20Dis.%202023;23(1):598." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>D:A:D study group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417–26.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(08)60423-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2688660/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18387667/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?D:A:D%20study%20group,%20Sabin%20CA,%20Worm%20SW,%20Weber%20R,%20Reiss%20P,%20El-Sadr%20W,%20et%20al.%20Use%20of%20nucleoside%20reverse%20transcriptase%20inhibitors%20and%20risk%20of%20myocardial%20infarction%20in%20HIV-infected%20patients%20enrolled%20in%20the%20D:A:D%20study:%20a%20multi-cohort%20collaboration.%20Lancet.%202008;371(9622):1417%E2%80%9326." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Sabin CA, Reiss P, Ryom L, Phillips AN, Weber R, Law M, et al. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? a cohort collaboration. BMC Med. 2016;14:61.
</cite> [<a href="https://doi.org/10.1186/s12916-016-0588-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4815070/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27036962/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sabin%20CA,%20Reiss%20P,%20Ryom%20L,%20Phillips%20AN,%20Weber%20R,%20Law%20M,%20et%20al.%20Is%20there%20continued%20evidence%20for%20an%20association%20between%20abacavir%20usage%20and%20myocardial%20infarction%20risk%20in%20individuals%20with%20HIV?%20a%20cohort%20collaboration.%20BMC%20Med.%202016;14:61." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023;389(8):687–99.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2304146" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10564556/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37486775/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Grinspoon%20SK,%20Fitch%20KV,%20Zanni%20MV,%20Fichtenbaum%20CJ,%20Umbleja%20T,%20Aberg%20JA,%20et%20al.%20Pitavastatin%20to%20prevent%20cardiovascular%20disease%20in%20HIV%20infection.%20N%20Engl%20J%20Med.%202023;389(8):687%E2%80%9399." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Lu MT, Ribaudo H, Foldyna B, Zanni MV, Mayrhofer T, Karady J, et al. Effects of pitavastatin on coronary artery disease and inflammatory biomarkers in HIV: mechanistic substudy of the REPRIEVE randomized clinical trial. JAMA Cardiol. 2024;9(4):323–34.
</cite> [<a href="https://doi.org/10.1001/jamacardio.2023.5661" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10882511/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38381407/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lu%20MT,%20Ribaudo%20H,%20Foldyna%20B,%20Zanni%20MV,%20Mayrhofer%20T,%20Karady%20J,%20et%20al.%20Effects%20of%20pitavastatin%20on%20coronary%20artery%20disease%20and%20inflammatory%20biomarkers%20in%20HIV:%20mechanistic%20substudy%20of%20the%20REPRIEVE%20randomized%20clinical%20trial.%20JAMA%20Cardiol.%202024;9(4):323%E2%80%9334." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, et al. Long-term safety and efficacy of emtricitabine and Tenofovir Alafenamide vs emtricitabine and Tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV. 2021;8(7):e397–407.
</cite> [<a href="https://doi.org/10.1016/S2352-3018(21)00071-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34197772/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ogbuagu%20O,%20Ruane%20PJ,%20Podzamczer%20D,%20Salazar%20LC,%20Henry%20K,%20Asmuth%20DM,%20et%20al.%20Long-term%20safety%20and%20efficacy%20of%20emtricitabine%20and%20Tenofovir%20Alafenamide%20vs%20emtricitabine%20and%20Tenofovir%20disoproxil%20fumarate%20for%20HIV-1%20pre-exposure%20prophylaxis:%20week%2096%20results%20from%20a%20randomised,%20double-blind,%20placebo-controlled,%20phase%203%20trial.%20Lancet%20HIV.%202021;8(7):e397%E2%80%93407." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12374459/bin/12879_2025_11476_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1.</a><sup> (418.8KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Gilead Sciences shares anonymized individual participant data upon request or as required by law or regulation with qualified external researchers based on submitted curriculum vitae that reflect no conflicts of interest. The request proposal must also include a statistician. Approval of such requests is at Gilead Science’s discretion and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data. Data requests should be sent to datasharing@gilead.com.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from BMC Infectious Diseases are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s12879-025-11476-3"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/12879_2025_Article_11476.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.3 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12374459/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12374459/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374459%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374459/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12374459/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12374459/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40846915/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12374459/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40846915/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12374459/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12374459/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="xXDiUGkuSXyPCgTte1Z4lKjwqMtTAbGq6048FJvMokTMsFDcsjZYt01fOJA7vKVN">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
